Well-known pharmaceutical company FangSheng Pharmaceuticals bought 6 large varieties.

Pharmaceutical Network September 16th, Fangsheng Pharmaceuticals announced that Fangsheng Pharmaceuticals and Hunan Kangjia Pharmaceutical signed a "drug variety transfer agreement." according to the
announcement, Fangsheng Pharmaceuticals decided to transfer the ownership of six drug varieties (including but not limited to the original development materials, drug prescriptions, production processes and quality standards, re-registration materials and new drug certificates and other production technologies and intellectual property rights) of RMB7 million.
The amount of specific varieties granted is as follows: Because these varieties belong to the public awareness of high, market sales of large varieties, in addition to intestinal capsules for the national exclusive dosage form (intestinal tablets have been approved for the production of 5 enterprises), the rest of the products in the market manufacturers are more.
The sales data of these varieties are as follows (some companies can not learn the relevant data from public sources): FangSheng Pharmaceuticals said in the announcement, the company to "drug listing license holder system" as an opportunity to actively reserve drug varieties with potential for development, enrich the company's product line, is conducive to promoting the integration of the industrial chain and industrial expansion, promote the company to become bigger and stronger quickly.
understood that in the acquisition of varieties at the same time, Fangsheng Pharmaceuticals has previously also transferred sales to foreign sales accounted for a small proportion of the revenue of varieties.
For example, in June last year, at a price of 11.95 million yuan, 9.35 million yuan, respectively, the re-pulsed capsules and the country's exclusive dosage form clear brain pressure-reducing particles of the drug production technology transferred to Da Song Pharmaceuticals;
fact, 2020 has been a very difficult year for Chinese medicine companies.
According to the Sichuan Cai Securities report, from the first half of 2020 listed pharmaceutical companies, the structure of the pharmaceutical industry, affected by the epidemic, in the first half of 2020, medical device companies' operating income increased significantly, up 39.61 percent year-on-year, and chemical raw materials increased by 4. 74%, medical services rose 4.11% YoY, pharmaceutical businesses, biological products and chemicals fell 1.39%, 3.63% and 8.98% YoY, respectively, while Chinese medicine declined by as much as 9.94%.
According to The same Huashun data show that under the Tonghuashun industry classification, 68 Chinese medicine classification enterprises, only 17 enterprises operating income increased year-on-year, accounting for 25%, only part of Ling Pharmaceuticals, Foci Pharmaceuticals and other pharmaceutical enterprises involved in the new crown pneumonia epidemic revenue growth is obvious.
75% of the enterprise income negative growth, the pressure on the Chinese medicine industry is still obvious, the down-line pressure is still greater.
the sale of subsidiaries, many listings have not been successful recently, Laimei Pharmaceuticals announced that it will continue to transfer the company's direct or indirect ownership of four subsidiaries in the Chongqing property rights trading network in the light of market conditions.
this is the 8th time that Lemme Pharmaceuticals has publicly listed a stake in a subsidiary.
it is understood that this is the 8th attempt by Lemme Pharmaceuticals to list since the asset transfer announcement was made on February 11.
announcement shows that the initial public listing price of the company through public listing transfer is not less than 70% of the equity evaluation value of the transaction target, and authorized the board of directors to reduce the listing price according to the actual situation, the reduction of not more than 50% of the initial listing price.
Initial listing is from March 23 to March 27, the company will directly or indirectly hold 100% of Hunan Kangyuan, Sichuan Yanzheng 100% equity, Lai U.S. mouse 70% equity and Laimei Health 60% of the shares entrusted to the Chongqing Stock Exchange initial public listing transfer, listing price of about 330 million yuan.
From the company's 2020 semi-annual report, the transfer of equity of the four subsidiaries, only One Sichuan Yanzheng profit (first-half net profit of 2.64 million yuan), the remaining three are in a loss-making state (the first half of Hunan Kangyuan loss of 17.42 million yuan, Laimei Health loss of 1.48 million yuan, Lai U.S. dollar rat loss of 1.95 million).
Leme Pharmaceuticals said in its 2020 semi-annual report that the listing is to avoid industry-to-industry competition between Zhongheng Group and the company and its subsidiaries, focusing core resources around the company's strategic development plan, and proposing to dispose of the equity of subsidiaries that may create competition problems and are not in line with future strategic plans.
company will actively take various ways to dispose of the relevant assets according to the actual situation, including but not limited to public listing transfer, the introduction of strategic investors, the sale of some assets, etc., in order to further optimize the company's asset structure.
number of unsuccessful transfers, as well as the performance of the four subsidiaries that have been transferred, have called a big question mark over the future direction of the deal and the final deal price after its success.
but there is no doubt that the company's intention to "slim down" and focus on the development of core areas is very firm.
while divesting its non-core business, Lemme Pharmaceuticals is further focusing on its core development areas.
today (September 14), Laimei Pharmaceuticals announced the signing of a strategic cooperation agreement between the company and Wuhan Youzhiyou Biopharmaceutical Co., Ltd.
according to the announcement, Lemmy Pharmaceuticals intends to directly invest in Youzhiyou Bio through a new equity investment fund, further strengthen in-depth cooperation, equity investment fund to increase the capital of Youzhiyou Bio, Youzhiyou Bio will be the research and development of ophthalmology drug Y400 (anti-VEGFA x anti) -ANG2 BsAb) Wet Macular Degeneration (nAMD) dual-specific antibody drugs in China (including Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan region) priority sales agent granted to Lemieque Pharmaceuticals or its designated related parties, the specific authorization matters are based on a formally signed agreement.
In addition, Lemex Pharmaceuticals will make use of industrial experience and resource advantages, and actively explore ways of further in-depth cooperation with Youzhiyou Bio, including but not limited to cooperation to expand innovative research and development projects, dual-resistant products market agent sales. More than
pharmaceutical companies to sell their assets this year, there have been more than 10 well-known pharmaceutical companies in the active "slim", they have to sell subsidiaries, some sell products, some auction assets, most of the original intention is to focus on the main industry, in-live funds.
Recently, st.com disclosed that it intends to transfer the company and its wholly-owned subsidiary, Shanghai Nyung Da Anli Biological Products Sales Co., Ltd., through a public listing bid on the Shanghai Stock Exchange, to take a 100% stake in Shanghai Ida Anli Life Technology Development Co., Ltd.
It is understood that Shanghai Ida Anli Life Technology Development Co., Ltd. was established on December 6, 2002, with a registered capital of 27 million yuan, 97% owned by D'OngLi, and 3% owned by Shanghai Ida Anli Bio products Sales Co., Ltd.
2017, Thyda an additional 70 million yuan to life science and technology companies.
business scope includes biological, pharmaceutical, health food and other professional areas of technology development, technical advice, technical services, technology transfer, medical equipment management, pharmaceutical wholesale, drug retailing, translation services, ticketing agents.
announcement shows that the transaction is conducive to optimizing the company's asset structure, effectively withdraw funds, improve asset operation efficiency, in order to focus resources to strengthen the company's core competitiveness, and further enhance the company's ability to continue operating, so as to promote the smooth implementation of the company's restructuring and transformation.
In addition to the above-mentioned companies, since this year, more than 10 pharmaceutical companies have sold their assets, including Kangmei, Dong A gum, People's Fu Pharmaceuticals, Tonghua Jinma, Tai'anTang, Tianshili, Xinbang Pharmaceuticals, Beida Pharmaceuticals, Lizhu Group, Northeast Pharmaceuticals, Haizheng Pharmaceuticals and so on.
these pharmaceutical companies are selling assets out of money back to reduce the debt burden, and some are "slimming down" to focus on the main business, to meet the expansion of the main business.
addition to the sale of assets, there are pharmaceutical companies through the acquisition of varieties to enrich their product lines, through mergers and acquisitions to strengthen their own advantages, expand the corporate map.
the impact of the epidemic overlay medical reform policy, in fact, by the impact of the new crown epidemic, the entire pharmaceutical industry is facing great challenges.
chinese medicine industry pressure is more obvious, auxiliary drug control fees and new drug declaration and approval policies, all need Chinese medicine enterprises to make a greater adjustment to the original business strategy.
in the post-epidemic era, it is a challenge and an opportunity for the pharmaceutical industry.
whether it is chemical pharmaceutical enterprises or Chinese medicine enterprises, we must adjust the strategy in a timely manner, focus on the core business, improve the research and development capabilities of enterprises, follow the pace of the industry, in order to go further and further on the road of development.
.